| pubmed-article:11906293 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11906293 | lifeskim:mentions | umls-concept:C0021641 | lld:lifeskim |
| pubmed-article:11906293 | lifeskim:mentions | umls-concept:C0441655 | lld:lifeskim |
| pubmed-article:11906293 | lifeskim:mentions | umls-concept:C0935929 | lld:lifeskim |
| pubmed-article:11906293 | lifeskim:mentions | umls-concept:C0679622 | lld:lifeskim |
| pubmed-article:11906293 | lifeskim:mentions | umls-concept:C0205314 | lld:lifeskim |
| pubmed-article:11906293 | lifeskim:mentions | umls-concept:C0289779 | lld:lifeskim |
| pubmed-article:11906293 | lifeskim:mentions | umls-concept:C0243072 | lld:lifeskim |
| pubmed-article:11906293 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:11906293 | pubmed:dateCreated | 2002-3-21 | lld:pubmed |
| pubmed-article:11906293 | pubmed:abstractText | Two novel classes of 2,4-thiazolidinediones and 2,4-oxazolidinediones with an omega-(azolylalkoxyphenyl)alkyl substituent at the 5-position were prepared and their antidiabetic effects were evaluated in two genetically obese and diabetic animal models, KKA(y) mice and Wistar fatty rats. A large number of the 2,4-thia(oxa)zolidinediones showed potent glucose- and lipid-lowering activities. The antidiabetic activities of the 2,4-oxazolidinediones were superior to those of the 2,4-thiazolidinediones. Among the compounds, both enantiomers of 5-[3-[4-[2-(2-furyl)-5-methyl-4-oxazolylmethoxy]-3-methoxyphenyl]propyl]-2,4-oxazolidinedione (64), one of the most interesting compounds in terms of activity, were synthesized by using an asymmetric O-acetylation of the corresponding alpha-hydroxyvalerate (26) with immobilized lipase, followed by cyclization of the oxazolidinedione ring. (R)-(+)-64 showed more potent glucose-lowering activity (effective dose (ED)25 = 0.561 mg/kg/d) than (S)-(-)-64 (ED25 > 1.5 mg/kg/d) or pioglitazone (ED25 = 6 mg/kg/d) in KKA(y) mice. It also exhibited a 10-fold more potent antidiabetic activity (ED25 = 0.05 mg/kg/d) than pioglitazone (ED25 = 0.5 mg/kg/d) in Wistar fatty rats. The antidiabetic effects of this compound are considered to be due to its potent agonistic activity for peroxisome proliferator-activated receptor gamma (EC(50) = 8.87 nM). | lld:pubmed |
| pubmed-article:11906293 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11906293 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11906293 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11906293 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11906293 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11906293 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11906293 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11906293 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11906293 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11906293 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11906293 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:11906293 | pubmed:issn | 0022-2623 | lld:pubmed |
| pubmed-article:11906293 | pubmed:author | pubmed-author:IkedaHitoshiH | lld:pubmed |
| pubmed-article:11906293 | pubmed:author | pubmed-author:MomoseYuY | lld:pubmed |
| pubmed-article:11906293 | pubmed:author | pubmed-author:MaekawaTsuyos... | lld:pubmed |
| pubmed-article:11906293 | pubmed:author | pubmed-author:OdakaHiroyuki... | lld:pubmed |
| pubmed-article:11906293 | pubmed:author | pubmed-author:SohdaTakashiT | lld:pubmed |
| pubmed-article:11906293 | pubmed:author | pubmed-author:YamanoTohruT | lld:pubmed |
| pubmed-article:11906293 | pubmed:author | pubmed-author:KawadaMitsuru... | lld:pubmed |
| pubmed-article:11906293 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11906293 | pubmed:day | 28 | lld:pubmed |
| pubmed-article:11906293 | pubmed:volume | 45 | lld:pubmed |
| pubmed-article:11906293 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11906293 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11906293 | pubmed:pagination | 1518-34 | lld:pubmed |
| pubmed-article:11906293 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:11906293 | pubmed:meshHeading | pubmed-meshheading:11906293... | lld:pubmed |
| pubmed-article:11906293 | pubmed:meshHeading | pubmed-meshheading:11906293... | lld:pubmed |
| pubmed-article:11906293 | pubmed:meshHeading | pubmed-meshheading:11906293... | lld:pubmed |
| pubmed-article:11906293 | pubmed:meshHeading | pubmed-meshheading:11906293... | lld:pubmed |
| pubmed-article:11906293 | pubmed:meshHeading | pubmed-meshheading:11906293... | lld:pubmed |
| pubmed-article:11906293 | pubmed:meshHeading | pubmed-meshheading:11906293... | lld:pubmed |
| pubmed-article:11906293 | pubmed:meshHeading | pubmed-meshheading:11906293... | lld:pubmed |
| pubmed-article:11906293 | pubmed:meshHeading | pubmed-meshheading:11906293... | lld:pubmed |
| pubmed-article:11906293 | pubmed:meshHeading | pubmed-meshheading:11906293... | lld:pubmed |
| pubmed-article:11906293 | pubmed:meshHeading | pubmed-meshheading:11906293... | lld:pubmed |
| pubmed-article:11906293 | pubmed:meshHeading | pubmed-meshheading:11906293... | lld:pubmed |
| pubmed-article:11906293 | pubmed:meshHeading | pubmed-meshheading:11906293... | lld:pubmed |
| pubmed-article:11906293 | pubmed:meshHeading | pubmed-meshheading:11906293... | lld:pubmed |
| pubmed-article:11906293 | pubmed:meshHeading | pubmed-meshheading:11906293... | lld:pubmed |
| pubmed-article:11906293 | pubmed:meshHeading | pubmed-meshheading:11906293... | lld:pubmed |
| pubmed-article:11906293 | pubmed:meshHeading | pubmed-meshheading:11906293... | lld:pubmed |
| pubmed-article:11906293 | pubmed:meshHeading | pubmed-meshheading:11906293... | lld:pubmed |
| pubmed-article:11906293 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:11906293 | pubmed:articleTitle | Novel 5-substituted 2,4-thiazolidinedione and 2,4-oxazolidinedione derivatives as insulin sensitizers with antidiabetic activities. | lld:pubmed |
| pubmed-article:11906293 | pubmed:affiliation | Medicinal Chemistry Research Laboratories II, and Strategic Research Planning, Pharmaceutical Research Division, Takeda Chemical Industries, Ltd., 17-85, Jusohonmachi 2-Chome, Yodogawaku, Osaka 532-8686, Japan. Momose_Yu@takeda.co.jp | lld:pubmed |
| pubmed-article:11906293 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:11906293 | lld:chembl |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11906293 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11906293 | lld:pubmed |
